Ketamine can relieve symptoms of depression and anxiety, therefore filling a critically unmet psychiatric need. A few small-scale clinical studies suggest serotonergic psychedelics may have similar therapeutic effects.
Ketamine may both enhance and suppress dendritic excitability, through microcircuit interactions involving disinhibition.
Serotonergic psychedelics may both enhance and suppress excitability, through targeting coexpressed receptors.
Spatial mismatch in the opposing drug actions on dendritic excitability is predicted to steer plasticity actions towards certain synapses and cell types.
We present a dendrite-focused framework as a novel lens to view the actions of ketamine and serotonergic psychedelics on cortical circuits.